About This Report

In 2009, TNF inhibitors were the dominant drug class in terms of sales. However, there is growing use of non-TNF biologics at earlier lines of treatment, and this trend will continue over the next decade. With the first Phase III data from tasocitinib (CP-690,550; Pfizer) reaffirming efficacy with no new safety signals, novel oral small molecules could revolutionize the treatment of RA.
What's Included in This Report?


* Get detailed data into the RA sector opportunity utilizing robust 10-year IMS- and patient-based projections, enabling commercial opportunity assessment
* Assess the future key competitors, with in-depth profiles of the leading industry ed biologics
* Evaluate future patient numbers and brand dynamics by line of therapy
* Enhance understanding of future product potential, with key opinion leader views of late stage agents in the pipeline, such as tasocitinib and FosD

Key Market Facts

New product launches, brand reformulations and further biologic uptake will grow the RA industry to over USD 13bn in 2019. Using a patient-based approach, Datamonitor speculates that the RA industry for biologics will double from 2009 to reach over 1million patients in 2019, translating to a value that could surpass USD 15bn.Datamonitor anticipates non-TNF biologics will be used more frequently at earlier lines of therapy. Bristol-Myers Squibb and Roche, which industry Orencia (abatacept) and Actemra (tocilizumab), respectively, are attempting to change the game, with subcutaneous formulations and head-to-head studies against Humira (adalimumab; Abbott, Eisai).Tasocitinib (CP-690,550; Pfizer) demonstrated efficacy with no new safety signals in its first set of Phase III data. Despite ongoing debate over annual cost and positioning, rheumatologists believe tasocitinib has the potential to be a paradigm changing drug, and will achieve blockbuster status in the projection period, reaching USD 1.3bn by 2019.

Why Should You Buy This Report?


* What is the anticipated uptake of Cimzia (certolizumab) and Simponi (golimumab) and can these displace sales of the entrenched TNF brands?
* How will first-, second-, third- and fourth-line and above biologic brand dynamics change in the RA industry across the 10-year projection period
* What is the potential industry impact from Pfizer’s tasocitinib, how will it be priced and how will rheumatologists position the novel small molecule?
* What impact will subcutaneous Orencia and Actemra have, and will these formulations help to propel non-TNFs further up the treatment algorithm?
* Who were the top industry player players in the rheumatoid arthritis industry in 2009 and how will the landscape change to 2019?

Table Of Contents

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022

  • $ 9 995
  • Industry report
  • March 2014
  • by Global Data

PharmaPoint: Parkinson's Disease - Global Drug Forecast and Market Analysis to 2022 Summary Parkinson's disease is a progressive condition that is characterized by bradykinesia, muscular rigidity, tremor, ...

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 9 995
  • Industry report
  • April 2014
  • by Global Data

PharmaPoint: Non-Small Cell Lung Cancer - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary Non-Small Cell Lung Cancer (NSCLC) is the most common lung cancer, and the second-most ...

Analytical Tool - Hematological Cancers

Analytical Tool - Hematological Cancers

  • $ 8 925
  • Industry report
  • March 2014
  • by Bioseeker

"Analytical Tool - Hematological Cancers" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in hematological cancers. It is ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.